Dr. William T. Carpenter Jr.

• 
  www.icspp.org/World-Opinion/Social-Network-s-Healing-Po - [Cached Version]
  Published on: 6/27/2005    Last Visited: 10/2/2008  

  "A culture like ours is oriented around individual autonomy and accomplishment," said William Carpenter, a psychiatrist at the University of Maryland in Baltimore who helped run a wing of the WHO study in the Washington area.
  ...
  Prince George's County outside Washington was one of the sites of the pioneering WHO study -- William Carpenter helped treat about 90 schizophrenia patients at three hospitals.That experience brought home to him the fact that medications primarily control patients' delusions and hallucinations, not the "negative" symptoms that cause patients to disappear into silent, inner worlds.
  
  "The bias has always been in the direction of reducing psychosis," said Carpenter, director of the Maryland Psychiatric Research Center."Psychosis is public and bothersome. . . . Negative symptoms bother you if it's your child, but it doesn't create a public disturbance."
  
  Anti-psychotic drugs that help quell the outward symptoms may actually exacerbate social withdrawal, he said: "While we treat one part of the illness, we potentially complicate another part of the illness."
  
  New medicines are being aimed at the negative symptoms.

• 
  www.schizophreniaforum.org/new/detail.asp?id=1332 - [Cached Version]
  Published on: 7/25/2008    Last Visited: 7/25/2008  

  Comment by: William Carpenter, SRF Advisor (Disclosure)
  
  Submitted 7 November 2007 Posted 8 November 2007
  
  Terrific update and summary for those of us not attending the meeting.
  
  View all comments by William Carpenter

• 
  news.psydir.com/Psychology-News/the-future-of-schizophr - [Cached Version]
  Published on: 3/30/2009    Last Visited: 7/12/2009  

  22nd Congress of the European College of Neuropsychopharmacology (ECNP), 12 - 16 September 2009, Istanbul, Turkey Professor William T. Carpenter from the Maryland Psychiatric Research Center, University of Maryland School of Medicine, USA, will present the major directions of current scientific activities and point to the clinical implications of this paradigm shift, which is influencing virtually all aspects of schizophrenia research. | Discuss | Bury

• 
  www.freedom-center.org/will-quoted-new-york-times-schiz - [Cached Version]
  Published on: 3/21/2006    Last Visited: 5/11/2007  

  "My personal view is that the pendulum has swung too far, and there's this knee-jerk reaction out there that says that any period off medication, even for research, is on the face of it unethical," said Dr. William Carpenter, director of the University of Maryland's Psychiatric Research Center and the editor of the journal Schizophrenia Bulletin, which will publish the article on April 1, along with several invited commentaries.
  
  Dr. Carpenter said that while antipsychotics are central to treatment in most cases the field's aggressive use of the drugs leaves "little maneuvering room" to try different options, like drug-free periods under close observation after a person's first episode of psychosis."It's a very controversial issue, and I thought it was important to get it out there," he said.

• 
  www.narsad.org/?q=node/128/prizes - [Cached Version]
  Last Visited: 9/8/2009  

  Dr. William Carpenter University of Maryland

• 
  www.narsad.org/dc/schizophrenia/featured.html - [Cached Version]
  Published on: 12/11/2006    Last Visited: 3/14/2007  

  Ethical Considerations in Medication-Free Research with Schizophrenia Patients: An Expert Interview with William T. Carpenter, Jr., M.D.
  ...
  On behalf of Medscape, Jessica E. Gould, B.A., interviewed William T. Carpenter, Jr., M.D., Editor-in-Chief, Schizophrenia Bulletin, Professor of Psychiatry and Pharmacology, University of Maryland School of Medicine, Baltimore, MD, and member of the Scientific Council of NARSAD: The Mental Health Research Association, about the ethical issues surrounding medication-free research.
  ...
  Dr. Carpenter: The Bola article in Schizophrenia Bulletin was a meta-analysis evaluating how subjects in research studies do when they are off medication.
  ...
  Dr. Carpenter: In general, the considerations include, first of all, how long they are going to be off medication.If they have a problem being off medication, how rapidly could medication be restored and is it likely to be effective?Will there be appropriate clinical observation?
  ...
  Dr. Carpenter: The first step toward safety, again, is excluding people at greatest risk.
  ...
  Dr. Carpenter: The ethics and principles for medication-free research would be the same as that which guides ethical oversight of any human subject research.
  
  If research is deemed justified by the scientific merit, you must ensure that it is also justified by having adequate safeguards to minimize risk.That risk should be comparable in proportion to the importance of the experiment.
  
  Medscape: Tell us about the issue of biological toxicity.
  
  Dr. Carpenter: There was a hypothesis that Richard Wyatt put forward some years ago that psychosis might, in and of itself, be neurotoxic.[2,3] If true, the implication would be that the more you experience psychosis, the worse it is for your brain tissue.
  ...
  Dr. Carpenter: There are many interesting hypotheses that require off-medication study designs.
  ...
  Dr. Carpenter: Many institutional review boards have a strongly negative approach toward off-medication research in schizophrenia.The cost of doing business has gotten extraordinarily high without there being any evidence that people are actually being harmed by participating in off-medication studies.
  ...
  Dr. Carpenter: The response from the field has been interesting.
  ...
  Dr. Carpenter: The basic issues would be the same.
  ...
  Dr. Carpenter: There is extensive non-adherence to medication.
  ...
  Interviewee affiliation: William T. Carpenter, Jr., M.D., Editor-in-Chief, Schizophrenia Bulletin; Professor, Psychiatry and Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland; founding member of the Scientific Council of NARSAD: The Mental Health Association
  ...
  Disclosure: William T. Carpenter, Jr., M.D., has disclosed no relevant financial relationships.

• 
  www.narsad.org/news/press/rg_2006/res2006-12-13.html - [Cached Version]
  Published on: 12/13/2006    Last Visited: 3/14/2007  

  Ethical Considerations in Medication-Free Research with Schizophrenia Patients: An Expert Interview with William T. Carpenter, Jr., M.D.NARSAD: News & Events: For the Media: News Article
  ...
  with William T. Carpenter, Jr., M.D.
  
  (Great Neck, NY - >) , In a recent article, posted on October 25, 2006, in Schizophrenia Bulletin, John R. Bola, PhD, of the University of Southern California, Los Angeles, asserted that there is insufficient evidence to conclude that short-term postponement of medication in early episodes results in long-term harm, and suggested reconsidering the categorical prohibition against medication-free research.
  
  On behalf of Medscape, Jessica E. Gould, B.A., interviewed William T. Carpenter, Jr., M.D., Editor-in-Chief, Schizophrenia Bulletin, Professor of Psychiatry and Pharmacology, University of Maryland School of Medicine, Baltimore, MD, and member of the Scientific Council of NARSAD: The Mental Health Research Association, about the ethical issues surrounding medication-free research.
  ...
  Dr. Carpenter: The Bola article in Schizophrenia Bulletin was a meta-analysis evaluating how subjects in research studies do when they are off medication.
  ...
  Dr. Carpenter: In general, the considerations include, first of all, how long they are going to be off medication.If they have a problem being off medication, how rapidly could medication be restored and is it likely to be effective?Will there be appropriate clinical observation?
  ...
  Dr. Carpenter: The first step toward safety, again, is excluding people at greatest risk.
  ...
  Dr. Carpenter: The ethics and principles for medication-free research would be the same as that which guides ethical oversight of any human subject research.
  
  If research is deemed justified by the scientific merit, you must ensure that it is also justified by having adequate safeguards to minimize risk.That risk should be comparable in proportion to the importance of the experiment.
  
  Medscape: Tell us about the issue of biological toxicity.
  
  Dr. Carpenter: There was a hypothesis that Richard Wyatt put forward some years ago that psychosis might, in and of itself, be neurotoxic.[2,3] If true, the implication would be that the more you experience psychosis, the worse it is for your brain tissue.
  ...
  Dr. Carpenter: There are many interesting hypotheses that require off-medication study designs.
  ...
  Dr. Carpenter: Many institutional review boards have a strongly negative approach toward off-medication research in schizophrenia.The cost of doing business has gotten extraordinarily high without there being any evidence that people are actually being harmed by participating in off-medication studies.
  ...
  Dr. Carpenter: The response from the field has been interesting.
  ...
  Dr. Carpenter: The basic issues would be the same.
  ...
  Dr. Carpenter: There is extensive non-adherence to medication.
  ...
  Interviewee affiliation: William T. Carpenter, Jr., M.D., Editor-in-Chief, Schizophrenia Bulletin; Professor, Psychiatry and Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland; founding member of the Scientific Council of NARSAD: The Mental Health Association
  ...
  Disclosure: William T. Carpenter, Jr., M.D., has disclosed no relevant financial relationships.

• 
  psych.org/MainMenu/Research/APIRE/APIREBoard.aspx - [Cached Version]
  Published on: 10/15/2008    Last Visited: 10/15/2008  

  William T. Carpenter, M.D. Professor, Psychiatry and Pharmacology University of Maryland School of Medicine

• 
  www.appi.org/book.cfm?id=62191 - [Cached Version]
  Published on: 4/8/2006    Last Visited: 3/4/2007  

  William T. Carpenter, Jr., M.D.
  ...
  Special issues such as comorbidity, first-episode patients, and clinical care in the public sector are addressed."- William T. Carpenter Jr., M.D., Professor of Psychiatry and Pharmacology, University of Maryland School of Medicine; Director, Maryland Psychiatric Research Center, Baltimore, Maryland

• 
  www.schizophreniaforum.org/abo/adv/sab2005_2009.asp - [Cached Version]
  Published on: 1/1/2005    Last Visited: 9/30/2009  

  William T. Carpenter, Jr., M.D. Professor of Psychiatry and Pharmacology University of Maryland School of Medicine

Page:  1 2 3 4 5